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The treatment of patients with malignant superior vena caval obstruction with 
minimal morbidity has been made possible by the recent introduction of 
expandable metal stents as the sole palliative treatment or as an adjunct to 
other treatment modalities. To alleviate the distressing symptoms of superior 
vena caval obstruction, self-expanding metal stents were used successfully in 
12 (Wallstent device in 6 and Gianturco device in 6 patients) of 13 patients. The 
diagnoses were small cell carcinoma (n = 4), squamous cell carcinoma (n = 4), 
non-Hodgkin's lymphoma (n = 1), and mesothelioma (n = 1), and a diagnosis 
of malignancy was not confirmed (although strongly suspected) in the remain- 
ing three cases. Eleven patients had immediate relief of obstruction and there 
was no change in one patient. Mean follow-up was 3.7 months (range 1 to 10 
months). Excellent palliation was obtained in all but one patient in whom 
recurrent superior vena caval obstruction developed 3 months after stenting. 
Mean survival was 4.8 months (range 1 to 10 months). The ease of insertion 
with the use of local anesthesia with radiologic control, the self-expanding 
nature of the stent, and the lack of major complications on follow-up of up to 
10 months are particular advantages. The self-expanding superior vena caval 
stents are a useful addition to our armamentarium in the management of 
malignant superior vena caval obstruction. (J Thorac Cardiovasc Surg 1996; 
112:335-40) 
S uperior vena caval (SVC) syndrome was first de- scribed by William Hunter in 1757.1 The SVC 
syndrome is caused by malignant disease in 85% to 
95% of reported cases. 2-4 The cause is bronchogenic 
carcinoma in about 80% of the cases, with lymphoma 
and metastatic disease comprising 15% and 5%, re- 
spectively. ~ Mediastinal inflammation as a result of 
fibrosing mediastinitis and granulomatous disease 
caused by histoplasmosis nfection predominate the 
benign canses of SVC syndrome. 4 With the advent of 
long-term central venous catheterization for diagnostic 
or therapeutic interventions, catheter-related throm- 
bosis of the SVC is being increasingly reported. 2' s 
The symptoms consist of venous congestion and 
edema of the upper half of the body. The prognosis 
is poor in the presence of upper airway obstruction 
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caused by edema or cerebral edema. 3 Bypass oper- 
ations, 6 radiation therapy, 7'8 and chemotherapy 9 
have been used to treat SVC syndrome. The indica- 
tions for operation are limited, and radiation ther- 
apy and chemotherapy are not promptly effective. 1° 
Recurrent SVC obstruction develops in 10% to 19% 
of the patients after radiotherapy. 2 Surgical manage- 
ment is associated with high morbidity and mortality 
particularly in patients with malignant disease with a 
short life expectancy. 
Percutaneous stent placement for the treatment 
of SVC obstruction has been previously reported 
with Gianturco stents 11-15 (William Cook Europe 
AS, Bjaerverskov, Denmark), Palmaz stents 16 
(Johnson & Johnson Interventional Systems, War- 
ren, N.J.), and Wallstent devices 17' 18 (Schneider 
Inc., Pfizer Hospital Product Groups, Minneapolis, 
Minn.). We present our experience of 13 patients, 
updating our previous report of two cases. 19 
Patients and methods 
Between May 1991 and March 1995, we placed self- 
expanding metal stents in 13 consecutive patients with 
clinical evidence of SVC obstruction. There were eight 
men and five women, with a mean age of 60 years (range 
52 to 74 years). Table I shows the demographic details of 
the patients and the causes of SVC obstruction. Eleven 
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Table I. Demographic details 
Patient No. Sex~age (yr) Diagnosis Stent Response Follow-up 
1 M/67  Small-cell carcinoma Gianturco, 2stents Good 10 months (died) 
2 F/60 R paratracheal mass Gianturco Good 2 months (died) 
3 M/79 R paratracheal mass Gianturco, 2 stents Poor 1 month (died) 
4 F/58 Small-cell carcinoma Gianturco, 2 stents Good 5 months (died) 
5 M/64 NHL of mediastinum Gianturco Good 6 months (died RTA) 
6 M/71 R paratracheal mass Gianturco, 4 stents Good 3 months (died) 
7 M/74  Recurrent squamous Wallstent Good 1 month 
cell carcinoma RUL 
8 M/52  Mesothelioma Wallstent Good Recurrent SVC 
obstruction 3 months 
9 M/68  Squamous cell carcinoma Wallstent Good 3 months (died) 
mediastinum 
10 F/58 Squamous cell Wallstent Good 5 months 
carcinoma RMB (thrombolysis+) 
11 F/59 Small-cell carcinoma Wallstent Good 1 month (died) 
12 M/68  Small-cell carcinoma Wallstent Good 5 months (died) 
13 F/63 Squamous cell carcinoma Unsuccessful - -  3 months (died) 
with mediastinal metastasis 
R, Right; NHL, non-Hodgkin's lymphoma; RTA, road traffic accident; RUL, right upper lobe; RMB, right main bronchus. 
patients had presenting symptoms of severe SVC obstruc- 
tion, and two patients had recurrent SVC obstruction 
after radiotherapy. Patients with upper airways compro- 
mised by laryngotracheal edema or with symptoms caused 
by cerebral edema were considered to have severe SVC 
obstruction. 
In all patients diagnosis was confirmed by venography 
(Figs. 1 and 2) before stenting. Histologic diagnosis of the 
cause of obstruction was confirmed by bronchoscopy or 
mediastinoscopy, or both, in 10 cases and in the remaining 
three cases histologic confirmation was not obtained 
despite high clinical and radiologic suspicion of malig- 
nancy. 
Stent insertion with the use of a local anesthetic with 
radiologic ontrol (see following section) was attempted 
in 13 patients and was technically successful in 12 patients. 
One patient needed thrombolytic treatment before stent 
placement. Six patients received Gianturco stents (earlier 
series) (Fig. 3) and the most recent six patients had 
Wallstent devices inserted (Fig. 4). Multiple Gianturco 
stents were used in five patients in the SVC and the left 
innominate vein. SIX patients received additional radio- 
therapy or chemotherapy after stent insertion. Two pa- 
tients had received radiotherapy previously and in the 
remaining five patients the condition was considered 
unsuitable for any additional treatment. Complete reso- 
lution of symptoms after stent placement was the criterion 
used to assess the success of the procedure. All patients 
were examined clinically by the thoracic surgeons and 
chest physicians. 
Technique of insertion. The technique of stent place- 
ment has been documented, 14' is and only the salient 
points of the technique are summarized here. 
1. Adequate demonstration of the relevart mediastinal 
venous anatomy is achieved with catheter placed from 
both arms. 
2. A guide wire is negotiated across the stenosed or 
occluded SVC. This is generally achievable with use of 
a supporting catheter and hydrophilic guide wire com- 
bination familiar to interventional radiologists. 
3. The stent is placed across the stenosed or occluded 
segment ensuring adequate coverage of the lesion, with 
use of an appropriately sized angioplasty balloon to aid 
stent expansion when necessary. The use of a long, very 
stiff exchange wire greatly facilitates this stage of the 
procedure, preventing coiling in the right atrium and 
allowing enough length to accommodate he long stent 
delivery system. 
4. A standard sized Wallstent device 12 mm in diameter 
and 9.6 cm long is adequate for all patients. 
5. The accurate placement required in most arterial set- 
tings is less important in SVC obstruction because of 
the length and diameter of the vessel and the availabil- 
ity of effective collateral channels. 
6. All patients receive 5000 units heparin before stent 
deployment and intravenous heparin (24,000 units/24 
hours) for 48 hours. 
7. Patients who required thrombolysis before stent place- 
ment receive long-term warfarin maintenance. 
Results 
The procedure was technically successful in 12 out 
of 13 cases, and fai lure was caused by complete 
occlusion of the SVC by extensive thrombus. In 10 
patients immediate rel ief of SVC obstruct ion was 
seen within 24 to 48 hours, in one pat ient  who had 
thrombolyt ic t reatment  previously clinical rel ief was 
not seen until 72 hours after stent p lacement,  and in 
the remaining one pat ient clinical status remained 
unchanged. 
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Mean follow-up was 3.7 months (range 1 to 10 
months). Recurrent SVC obstruction occurred in 
only one patient (patient 8) 3 months after initial 
stent insertion. Repeat venogram showed throm- 
botic occlusion, which responded effectively to 
thrombolytic treatment and placement of a second 
Wallstent device within the original stent. Ten pa- 
tients died during the follow-up period with a mean 
survival of 4.8 months (range 1 to 10 months). 
Discussion 
Various modalities of treatment have been advo- 
cated for the management of SVC obstruction. With 
recent advances in percutaneous interventional vas- 
cular technology thrombolytic agents, angioplasty, 
and intravascular stents have been used in the 
management of SVC obstruction. 11-13' 2o-22 Conven- 
tional treatment of this condition has been by radio- 
therapy, although chemotherapy is of value in small 
cell carcinoma. 23Although radiotherapy is success- 
ful in relieving obstruction caused by sensitive tu- 
mors such as lymphoma the success rate with bron- 
chial carcinoma is less consistent. 3 Remission rates 
of 76% are quoted in such situations. 24Surgical 
procedures such as venous bypass grafts or pericar- 
dial grafts necessitate major operations in patients 
with limited l~fe expectancy. 4' 25 
The intraluminal self-expanding metallic stents 
can be placed percutaneously under local anesthesia 
with radiologic control. The stent can be com- 
pressed and introduced through a Teflon polytetra- 
fluoroethylene catheter sized 8F to 12F depending 
on the caliber of the wire and the diameter of the 
stent. When the stent is released from the catheter, 
it expands to its original diameter. The expansion 
force varies with the caliber of the wire, the diame- 
ter and the length of the stent, and the number and 
angle of the bends. 26 When placed in the venous 
system, stents gradually are covered by the tunica 
intima and incorporated into the vascular wall 
within a few weeks, without impairing the patency 
of the side branches. 11The length of the stenosis 
does not preclude stent insertion because multiple 
stents can he inserted at the same time as in this 
series. For long strictures that require multiple 
stents, the distal stent should be placed first. The 
major disadvantage of the Gianturco stent used in 
the early part of this series i its shorter length and 
its potential to allow tumor ingrowth through its 
wider gap between the stent wires. The Wallstent 
device maintains the advantage of the metal stent, 
and its narrow woven mesh, greater flexibility, and 
Fig. 1. Digital subtraction venogram in patient with SVC 
obstruction. 
longer length make it superior to the Gianturco 
stent. 
Patients who are unable to lie flat, those with 
chronic complete vessel occlusion or severe coagu- 
lopathy, and those with cardiac failure are unsuit- 
able candidates for intravascular stent place- 
ment)7, 28 Pulmonary edema because of a sudden 
increase in venous return after SVC stent placement 
has been reported. 29For SVC obstruction caused by 
benign diseases the stent insertion should be ap- 
proached with caution. It should only be considered 
in patients in whom other techniques of palliation 
have failed or are hazardous. The follow-up to date 
after such procedures in these patients has been 
relatively short. However, restenosis as a result of 
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Fig. 2. Venogram demonstrating complete obstruction of SVC and brachiocephalic veins. 
epithelial hyperplasia would not preclude palliation 
by other means. 14 
We have demonstrated a failure rate of 7.1% with 
the Gianturco stent with no restenosis. This com- 
pares favorably with the failure rate of 7.7% and 
restenosis rate of 14.3% reported in 91 patients in 
the literature. 14'16,27, 28-3o There have been fewer 
reports on the use of the Wallstent device. Reported 
rates of failure and restenosis after Wallstent device 
insertion are 0% and 9%, with the corresponding 
rates for our patients in this series at 0% and 16.6%, 
respectively.l& 31
In a recent review of 56 procedures for relief of 
SVC obstruction a morbidity rate of 29% and a 
mortality rate of 4% were observed. 27 The reported 
complications were stent misplacement (10%), stent 
occlusion (10%), stent migration (5%), and chest 
pain (4%). 27 In this series thrombotic stent occlu- 
sion was the only complication seen in one patient 
(patient 8) and there was no stent-related mortality. 
Cardiac arrhythmias and stent breakage have also 
been reported. 27 The antagonistic movements of 
cardiac contraction, diaphragmatic excursion, and 
tumor compression probably contribute to the 
mechanism of breakage. 27 
The stents are thrombogenic and it was initially 
thought that patients required a short period of 
anticoagulation. Rosch and associates 12used long- 
term anticoagulation routinely, whereas Irving and 
colleagues 14 did not. However, both groups had 
almost identical long-term patency rates. In one 
patient in our series thrombotic occlusion occurred, 
which was effectively treated by thrombolytic treat- 
ment and placement of a second stent. Anticoagu- 
lation therapy after a stent procedure is indicated if 
there is a risk of thromboembolism. However, the 
benefits of this measure should be weighed against 
the risk of bleeding complications and inconve- 
nience to terminally ill patients. If thrombus is 
present initially, it should be lysed before stent 
placement, as in patient 10 in our series. 2& 32 Fol- 
low-up periods of up to 1 year in SVC stents and 2 
years in inferior vena caval stents have demon- 
strated long-term patency of these devices. 27 In our 
series the stent was patent up to 10 months after 
insertion in patient 1. 
From our experience and that of others 12'27 there 
is no doubt that stenting is an effective treatment for 
SVC obstruction. What remains to be decided is the 
timing of the the treatment. Certainly stenting 
should be the treatment of choice in unrelieved 
obstruction after treatment and in patients with 
recurrent obstruction after initially successful treat- 
ment and even as a primary treatment modality for 
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Fig. 4. Wallstent device in SVC (same patient as in 
Fig. 2). 
Fig. 3. Chest radiograph showing Gianturco stent in SVC 
(same patient as in Fig. 1). 
patients who are unfit or in those with threatened 
cerebral and laryngeal edema. It is a simple, safe, 
rapidly effective, minimally invasive technique for 
management of SVC obstruction. 
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